 NEW YORK, June 14, 2021 GLOBE NEWSWIRE -- Avenue Therapeutics, Inc. NASDAQ: ATXI Avenue, a company focused on the development of intravenous IV tramadol for the U.S. market, today announced that it has received a second Complete Response Letter CRL from the U.S. Food and Drug Administration FDA regarding its New Drug Application NDA seeking approval for IV tramadol. 